| Guo, Jun |
| Active, not recruiting | 3 | 390 | RoW | CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus | AnewPharma | Renal Cell Cancer Metastatic | 02/21 | 12/21 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | TQB2450, Anlotinib, Sunitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Renal Cancer | 06/25 | 12/25 | | |
NCT06738251: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma |
|
|
| Not yet recruiting | 3 | 402 | RoW | SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium for Injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Urothelial Carcinoma | 07/26 | 09/27 | | |
NCT05647954: A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver |
|
|
| Not yet recruiting | 3 | 350 | RoW | HX008 + TACE, Temozolomide + TACE, Pembrolizumab | Taizhou Hanzhong biomedical co. LTD | Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms | 12/24 | 06/25 | | |
| Recruiting | 3 | 340 | RoW | OH2, Salvage chemotherapy or best supportive care | Binhui Biopharmaceutical Co., Ltd. | Melanoma | 03/25 | 03/26 | | |
RC48-C016, NCT05302284: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma |
|
|
| Recruiting | 3 | 452 | RoW | RC48-ADC, Disitamab Vedotin, Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin | RemeGen Co., Ltd. | Urothelial Carcinoma, HER2-expressing | 12/26 | 04/28 | | |
NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma |
|
|
| Recruiting | 3 | 165 | RoW | tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin | Shanghai Kechow Pharma, Inc. | Melanoma | 09/27 | 09/27 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
| Active, not recruiting | 2 | 119 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Melanoma | 08/20 | 11/21 | | |
RC48-C009, NCT03809013: A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Completed | 2 | 64 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Urothelial Carcinoma | 03/21 | 06/23 | | |
NCT04200040: A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients |
|
|
| Recruiting | 2 | 165 | RoW | OrienX010 injection, Recombinant Human GM-CSF Herpes Simplex Virus Injection, Dacarbazine (DTIC) | OrienGene Biotechnology Ltd. | Melanoma (Skin) | 12/22 | 12/22 | | |
| Completed | 2 | 100 | RoW | HL-085 | Shanghai Kechow Pharma, Inc. | Melanoma | 02/23 | 02/23 | | |
NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | QLF31907 | Qilu Pharmaceutical Co., Ltd. | Melanoma, Urothelial Carcinoma | 10/23 | 07/24 | | |
NCT05135715: A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) |
|
|
| Recruiting | 2 | 50 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Melanoma, Stage II, HER2-positive, Advanced Melanoma | 12/24 | 12/25 | | |
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer |
|
|
| Recruiting | 2 | 115 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Bladder Urothelial Cancer | 12/24 | 06/25 | | |
NCT06227156: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin Injection, DV,RC48 | RemeGen Co., Ltd. | Castration-resistant Prostate Cancer | 12/25 | 06/26 | | |
RC48-C017, NCT05297552: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 40 | RoW | RC48-ADC, JS001 | RemeGen Co., Ltd. | Muscle Invasive Bladder Carcinoma | 06/24 | 02/25 | | |
NCT05263453: HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation |
|
|
| Recruiting | 2 | 104 | RoW | HL-085, Vemurafenib | Shanghai Kechow Pharma, Inc. | Melanoma | 09/24 | 12/24 | | |
SHR-4602-202, NCT06704828: A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 20 | RoW | SHR-4602 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 04/27 | 04/27 | | |
MIZAR-003, NCT06703398: A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 98 | RoW | GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin | Shanghai Juncell Therapeutics | Melanoma | 07/26 | 12/26 | | |
NCT06797297: A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy |
|
|
| Not yet recruiting | 2 | 180 | RoW | IBI363, Pembrolizumab | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 03/26 | 06/27 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 120 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 06/25 | 07/26 | | |
NCT03676946: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 15 | RoW | ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg | Lee's Pharmaceutical Limited | Urothelial Carcinoma | 02/20 | 06/23 | | |
NCT03973151: Study of HL-085 in NRAS Mutant Advanced Melanoma |
|
|
| Completed | 1/2 | 42 | RoW | HL-085 | Shanghai Kechow Pharma, Inc. | Melanoma | 01/21 | 01/21 | | |
NCT05258266: A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 76 | RoW | ZX-101A | Nanjing Zenshine Pharmaceuticals | Advanced Solid Tumor | 06/23 | 04/24 | | |
NCT06359860: A Study of ST-1898 for Unresectable or Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 64 | RoW | ST-1898 tablets | Beijing Scitech-Mq Pharmaceuticals Limited | Unresectable or Metastatic Melanoma | 09/25 | 09/25 | | |
NCT04616443: OH2 Injection in Combination With HX008 for Melanoma. |
|
|
| Recruiting | 1/2 | 60 | RoW | OH2 injection, HX008 injection | Binhui Biopharmaceutical Co., Ltd. | Melanoma | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04618393: A Study of EMB-02 in Participants With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 47 | US, RoW | EMB-02 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumors | 07/23 | 03/24 | | |
NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 42 | RoW | T3011 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Melanoma | 09/25 | 09/25 | | |
NCT06209580: AMT-253 in Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 96 | RoW | AMT-253 for injection | Multitude Therapeutics Inc. | Malignant Melanoma, Advanced Solid Tumors | 04/25 | 12/25 | | |
| Recruiting | 1/2 | 30 | RoW | OH2 injection, Keytruda, pembrolizumab | Binhui Biopharmaceutical Co., Ltd. | Solid Tumor, Melanoma | 03/25 | 12/25 | | |
NCT06727630: A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 40 | RoW | PRJ1-3024 | Zhuhai Yufan Biotechnologies Co., Ltd | Melanoma | 04/25 | 10/25 | | |
| Recruiting | 1/2 | 80 | RoW | SHR-A2102, SHR-A2102 ; Adebrelimab injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 07/27 | 07/27 | | |
| Recruiting | 1/2 | 84 | RoW | KD6001, Toripalimab, JS001 | Shanghai Kanda Biotechnology Co., Ltd. | Melanoma | 12/24 | 12/25 | | |
NCT05794425: Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders |
|
|
| Recruiting | 1/2 | 100 | RoW | Cyclosporine A, Umbilical cord blood & Umbilical cord derived mesenchymal stem cells | Shandong Qilu Stem Cells Engineering Co., Ltd., Shandong Provincial Third Hospital, Dezhou People's Hospital, Children's Hospital Affiliated to Shandong University, The Second Affiliated Hospital of Shandong First Medical University, Tai'an Central Hospital, Linyi People's Hospital, Linyi Central Hospital, Rizhao People's Hospital, Lanling People's Hospital, Shandong Jining No.1 People's Hospital, The affiliated hospital of Jining medical college, Zibo municipal hospital, Binzhou People's Hospital, The Affiliated Hospital of Binzhou Medical College, Shengli Oilfield Central Hospital, Weihai Municipal Hospital, Weihai Central Hospital, The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine (TCM), Wuwei People's Hospital, Gansu Wuwei Tumour Hospital, The Second Affiliated Hospital of Harbin Medical University, Yuncheng Institute of Hematology, Kaifeng Central Hospital, Zhengzhou Central Hospital, Air Force Hospital of Western War Zone, The First People' s Hospital of Yunnan Province, Zigong No.1 Peoples Hospital, The First People's Hospital of Jingzhou, Jiangxi Province Children's Hospital, Second Affiliated Hospital of Zhengzhou University, Shandong University of Traditional Chinese Medicine, Yantai Ludong Hospital (Shandong Provincial Hospital Group) | Bone Marrow Failure Disorders | 04/25 | 04/26 | | |
| Recruiting | 1/2 | 20 | RoW | GC101 TIL | Shanghai Juncell Therapeutics | Tumor Infiltrating Lymphocytes, Safety, Melanoma, Efficacy, Adverse Drug Event | 04/25 | 07/25 | | |
Triumph-01, NCT05909436: Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors |
|
|
| Recruiting | 1/2 | 107 | RoW | GLS-012, GLS-010 | Guangzhou Gloria Biosciences Co., Ltd. | Solid Tumor | 12/26 | 12/26 | | |
NCT06079112: 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer |
|
|
| Recruiting | 1/2 | 100 | RoW | 9MW2821, 9MW2821 injection, Toripalimab, Toripalimab injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/27 | | |
TWP-101-11, NCT04871334: Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 1a/1b | 76 | RoW | TWP-101, Sytalizumab Injection | Shandong TheraWisdom Biopharma Co., Ltd. | Advanced Melanoma, Advanced Urothelial Carcinoma | 10/22 | 12/22 | | |
NCT06049030: A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma |
|
|
| Not yet recruiting | 1a/1b | 190 | NA | HS-10516 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Renal Cell Carcinoma | 09/24 | 09/25 | | |
NCT04756934: A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma |
|
|
| Recruiting | 1 | 63 | RoW | HX008, LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Melanoma | 08/21 | 08/22 | | |
NCT03932253: MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) |
|
|
| Suspended | 1 | 79 | RoW | FCN-159 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Melanoma | 04/23 | 04/24 | | |
NCT04842630: A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors |
|
|
| Terminated | 1 | 11 | RoW | SHR-1916 | Jiangsu HengRui Medicine Co., Ltd. | Unspecified Adult Solid Tumor, Protocol Specific | 11/22 | 11/22 | | |
TQB2618-Ib-01, NCT05451407: Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma |
|
|
| Recruiting | 1 | 50 | RoW | TQB2618 injection, Toripalimab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Melanoma | 10/23 | 12/23 | | |
NCT04727164: Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab |
|
|
| Not yet recruiting | 1 | 61 | NA | HBM4003 and Triprilimab, HBM4003 | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 11/23 | 11/23 | | |
NCT04640545: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma |
|
|
| Recruiting | 1 | 88 | RoW | LBL-007, Toripalimab, Axitinib Tablets | Nanjing Leads Biolabs Co.,Ltd | Advanced Melanoma | 07/25 | 12/25 | | |
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 1 | 45 | RoW | B001 injection, Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | NMO Spectrum Disorder | 12/25 | 12/25 | | |
NCT06155084: A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients |
|
|
| Recruiting | 1 | 62 | RoW | HP518 - Dose Escalation, Part 1 - Dose Escalation, HP518 -Dose Expansion, Part 2 - Dose Expansion Oral tablet(s) | Hinova Pharmaceuticals Inc. | Metastatic Castration-resistant Prostate Cancer | 07/26 | 09/26 | | |
NCT05393427: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors | 06/25 | 06/25 | | |
NCT06220838: Study SC-101 in Subjects with Advanced Malignancies |
|
|
| Recruiting | 1 | 100 | RoW | SC-101 | Tianjin ConjuStar Biologics Co., Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
NCT06321250: A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 80 | RoW | JMKX003948 | Jemincare, Zhejiang Hangyu Pharmaceutical Co., Ltd | Renal Cell Carcinoma Metastatic | 05/26 | 04/27 | | |
NCT05148325: Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 64 | RoW | BAT4706 | Bio-Thera Solutions, Peking University Cancer Hospital & Institute | Advanced Solid Tumor, Melanoma | 12/24 | 12/24 | | |
NCT05773937: A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Solid Tumors | 12/24 | 12/24 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Recruiting | 1 | 252 | RoW | SHR-A2102 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Or Metastatic Solid Tumor Malignancies | 08/25 | 08/25 | | |
NCT05766527: A Study of KM602 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 38 | RoW | KM602 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumor | 12/25 | 12/26 | | |
| Zhang, Bo |
NCT06263348: A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes |
|
|
| Recruiting | 4 | 2000 | RoW | Dorzagliatin tablets | Hua Medicine Limited, Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd. | Type2diabetes | 04/26 | 04/26 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Recruiting | 1/2 | 300 | RoW | OH2 injection, with or without irinotecan or HX008 | Binhui Biopharmaceutical Co., Ltd. | Solid Tumor, Gastrointestinal Cancer | 08/25 | 08/25 | | |
NCT04762602: A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations |
|
|
| Active, not recruiting | 1 | 90 | Europe, US | HMPL-306 | Hutchmed | Isocitrate Dehydrogenase Gene Mutation | 03/25 | 09/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
COOPERATION, NCT04912518: Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction |
|
|
| Recruiting | N/A | 250 | RoW | Dexmedetomidine (DEX), Placebo (Saline) | Harbin Medical University, Yangtze River Pharmaceutical Group Co., Ltd. | ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection | 12/24 | 12/25 | | |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
| Wang, Li Yong |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) |
|
|
| Active, not recruiting | 3 | 294 | Europe, US, RoW | AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol | Advenchen Laboratories, LLC, Advenchen Laboratories, LLC | Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma | 10/24 | 12/24 | | |
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
NCT04859621: Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections |
|
|
| Recruiting | 2 | 150 | RoW | Vitamin D3 4000 IU, Vitamin D3 2000 IU, Placebo, standard antibiotic therapy | Zensun Sci. & Tech. Co., Ltd. | Recurrent Urinary Tract Infection | 04/25 | 07/25 | | |
NCT05764590: A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients |
|
|
| Completed | 2 | 55 | RoW | AP-306, Sevelamer Carbonate | Alebund Pharmaceuticals | Chronic Kidney Diseases, Hyperphosphatemia | 08/23 | 09/23 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
| Not yet recruiting | 2 | 33 | RoW | TQB3616 capsule+Fulvestrant Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 05/26 | 12/26 | | |
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer |
|
|
| Recruiting | 2 | 460 | RoW | HS-20089 | Hansoh BioMedical R&D Company | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 12/25 | 12/27 | | |
NCT05551507: IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer |
|
|
| Recruiting | 1/2 | 150 | RoW | IN10018 in combination with PLD, IN10018 add on to PLD treatment | InxMed (Shanghai) Co., Ltd. | Platinum-resistant Ovarian Cancer | 06/24 | 12/24 | | |
NCT05186012: APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 51 | RoW | APG-1252, Pelcitoclax, Chidamide | Ascentage Pharma Group Inc. | NHL, Adult | 09/25 | 03/26 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia |
|
|
| Completed | 1 | 46 | US, RoW | APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Ascentage Pharma Group Inc. | Waldenstrom Macroglobulinemia | 02/24 | 02/24 | | |
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML |
|
|
| Recruiting | 1 | 198 | RoW | LP-108, Azacitidine | Guangzhou Lupeng Pharmaceutical Company LTD. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 12/24 | 12/25 | | |
NCT05119647: A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter |
|
|
| Completed | N/A | 124 | RoW | Thrombus Aspiration Catheter(Ton-bridgeMT) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Acute Ischemic Stroke | 08/22 | 11/22 | | |
| Liu, Ying Su |
NCT04468529: Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 154 | RoW | Recombinant human Neuregulin for injection, Neucardin, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 04/22 | 04/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia |
|
|
| Terminated | 2/3 | 23 | Europe, US, RoW | SLS-005, Placebo | Seelos Therapeutics, Inc. | Spinocerebellar Ataxia Type 3 | 11/23 | 11/23 | | |
MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 86 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 12/22 | 08/23 | | |
NCT05188209: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. |
|
|
| Recruiting | 2 | 60 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma | 03/23 | 08/23 | | |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT04774419: Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery |
|
|
| Recruiting | 2 | 62 | US | Intensity modulated radiation therapy (IMRT), Dostarlimab, TSR-042, Hypofractionated IMRT | Memorial Sloan Kettering Cancer Center, Tesaro, Inc. | Endometrial Cancer | 02/26 | 02/26 | | |
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD |
|
|
| Active, not recruiting | 2 | 237 | Europe, Canada, US | BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo | Bial R&D Investments, S.A. | Parkinson's Disease | 03/26 | 07/26 | | |
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 140 | RoW | D1553, IN10018（Ifebemtinib）, BI 853520 | InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd | Solid Tumor | 12/25 | 12/26 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
| Recruiting | N/A | 70 | US | | Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals | Parkinson Disease | 08/25 | 09/25 | | |
| Chen, Jianying |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
